MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

发表于 2026-7-8 10:05:23

期刊：Annals of Oncology

文献作者：M. Aldea; S.M. Lenahan; M.-A. Locquet; L. Liao; M. Gasparro; P.C. Gokhale; M.-R. Ghigna; D.N. Ionescu; I. Odintsov; K. Ngo; X. Wang; S. Aziz; F. Pecci; E. Garbo; E. Ivanova; S. Nakazawa; J. Kulesza; J.A. Tsai; L. Zullo; J. Lee; M. Zielinska; S. Simon; D. Han; A. Marinello; G. Li; G. Rossato de Almeida; J. Huang; F. Paoloni; E. Gariazzo; V. Santo; J. Remon; J.A. Marks; J. LoPiccolo; N. Florez; M. Nishino; B. Ricciuti; J. Luo; D.A. Barbie; D. Planchard; J.K. Rotow; F. Barlesi; R.P. Graf; W.W. Feng; B. Besse; C. Paweletz; L. Sholl; A.T. Shaw; P.A. Janne

出版日期：2026-7-

DOI号：10.1016/j.annonc.2026.03.001

下载链接：https://www.sciencedirect.com/sc ... 923753426000992/pdf

文献链接：https://doi.org/10.1016/j.annonc.2026.03.001

当前文献来源于 Elsevier BV。

备注信息：

[Elsevier/Sciencedirect] MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies 一键复制

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies